Mimedx (MDXG) Receivables (2010 - 2026)

Mimedx has disclosed Receivables across 17 years of filings, most recently posting $56.1 million for Q2 2026.

• In Q2 2026, Receivables fell 23.33% year-over-year to $56.1 million; the TTM figure through Jun 2026 stood at $56.1 million (down 23.33% YoY), while the FY2025 annual figure was $84.4 million, up 40.78% from the prior year.
• Receivables came in at $56.1 million for Q2 2026 at Mimedx, up from $55.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $84.4 million in Q4 2025 to a low of $39.1 million in Q1 2022.
• Average Receivables over 5 years is $57.5 million, with a median of $56.1 million recorded in 2024.
• Year-over-year, Receivables soared 47.2% in 2025 and declined 23.33% in 2026.
• Over 5 years, Receivables stood at $48.3 million in 2022, then grew by 20.2% to $58.0 million in 2023, then gained by 3.35% to $60.0 million in 2024, then surged by 40.78% to $84.4 million in 2025, then slumped by 33.54% to $56.1 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $56.1 million in Q2 2026, $55.6 million in Q1 2026, and $84.4 million in Q4 2025.